Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, and Placebo-Controlled Study to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination Versus Sumatriptan in the Acute Treatment of Migraine With Nausea

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, and Placebo-Controlled Study to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination Versus Sumatriptan in the Acute Treatment of Migraine With Nausea

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALLOD 2 (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura; Nausea
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Allodynic Therapeutics

    • Most Recent Events

    • 10 May 2018 Status changed from recruiting to completed.
    • 29 Oct 2017 Planned number of patients changed from 90 to 60.
    • 11 Jul 2017 Planned End Date changed from 27 Oct 2018 to 1 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top